Increased secreted amyloid precursor protein-α (sAPPα) in severe autism: proposal of a specific, anabolic pathway and putative biomarker.

Similarly, plasma Aβ1-42 levels demonstrated no change in patients with mild-to-moderate autism as compared to controls but a nearly significant decrease (∼50%) in severely autistic patients as compared to controls following ANOVA (F = 3.340, p = 0.047) and post-hoc Dunnett's multiple comparison test (p = 0.055) ( Figure 3B ).

also in 3,349 other papers